The Study
Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
This study gave two different diabetes medicines to 35 people and checked how their bodies reacted when their blood sugar was lowered on purpose. It found both medicines worked similarly — but it didn't test if they actually stop low blood sugar from happening in real life.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested two diabetes drugs — one that boosts natural hormones and one that mimics a gut hormone — to see if they hurt the body’s ability to fight low blood sugar.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 560 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Even though some stress hormones dropped, blood sugar still recovered normally — meaning the body didn’t get stuck in low sugar mode.
- 2Both drugs kept glucagon (a sugar-boosting hormone) working during low blood sugar.
- 3But they reduced other stress hormones like adrenaline and cortisol.
- 4One drug raised GIP levels; the other lowered mealtime sugar more.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes, Obesity & Metabolism
Year
2016
Authors
D. Yabe, T. Eto, M. Shiramoto, S. Irie, K. Murotani, Y. Seino, H. Kuwata, T. Kurose, S. Seino, B. Ahrén, Y. Seino
Related Content
Claims (4)
In Japanese adults with type 2 diabetes, two weeks of treatment with linagliptin or liraglutide does not reduce the increase in plasma glucagon levels when blood sugar is lowered to 2.5 mmol/L during a controlled test.
In Japanese adults with type 2 diabetes, two weeks of treatment with linagliptin or liraglutide reduces the increase in growth hormone, cortisol, epinephrine, and norepinephrine during induced low blood sugar compared to before treatment.
In Japanese adults with type 2 diabetes, linagliptin and liraglutide do not slow the return of blood glucose to normal levels after a hypoglycemic episode induced by insulin infusion.
In Japanese adults with type 2 diabetes, liraglutide lowers blood glucose after meals more than linagliptin after two weeks of treatment, while both drugs have similar effects on the body's response to low blood sugar.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.